Actavis Inc (ACT.N)

ACT.N on New York Stock Exchange

135.78USD
4:01pm EDT
Price Change (% chg)

$1.51 (+1.12%)
Prev Close
$134.27
Open
$134.76
Day's High
$136.09
Day's Low
$134.76
Volume
246,658
Avg. Vol
323,958
52-wk High
$136.29
52-wk Low
$73.86

ACT.N

Chart for ACT.N

About

Actavis, Inc. formerly Watson Pharmaceuticals, Inc., is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses... (more)

Overall

Beta: 0.36
Market Cap (Mil.): $17,878.37
Shares Outstanding (Mil.): 133.15
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -4.25 -- --
ROI: -6.96 19.48 18.76
ROE: -15.86 20.17 19.59
Search Stocks

Warner Chilcott markets $4.4 billion deal

NEW YORK - Specialty pharmaceutical Warner Chilcott Plc is in market with $4.4 billion in credit facilities that will refinance and combine debt following the company's acquisition by drug manufacturer Actavis Inc , sources told Thomson Reuters LPC.

03 Jul 2013

RLPC: Warner Chilcott markets $4.4B deal

NEW YORK, July 3 - Specialty pharmaceutical Warner Chilcott Plc is in market with $4.4 billion in credit facilities that will refinance and combine debt following the company's acquisition by drug manufacturer Actavis Inc, sources told Thomson Reuters LPC.

03 Jul 2013

U.S. justices say FTC can challenge deals to keep generic drugs off market

WASHINGTON, June 17 - The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals that brand-name drug companies make with generic rivals to keep cheaper products off the market.

17 Jun 2013

PRESS DIGEST - Financial Times - May 21

Essar Oil to sign fuel-for-cash deal with China Development Bank

20 May 2013

Actavis to buy Warner Chilcott in $5 billion stock deal

- Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.

20 May 2013

UPDATE 4-Actavis to buy Warner Chilcott in $5 billion stock deal

May 20 - Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.

20 May 2013

CORRECTED-UPDATE 1-Actavis to buy Warner Chilcott in $5 billion stock deal

(Corrects to show deal value of $5 billion, not $8.5 billion)

20 May 2013

US STOCKS-Futures little changed after records, acquisitions eyed

* Actavis to acquire Warner Chilcott in stock-for-stock deal

20 May 2013

Actavis to buy Warner Chilcott in $8.5 bln deal

May 20 - Generic drugmaker Actavis Inc will buy specialty pharmaceuticals company Warner Chilcott Plc in a stock deal valued at about $8.5 billion.

20 May 2013

BRIEF-Actavis says to buy Warner Chilcott for $8.5 bln

May 20 - Actavis Inc : * Recommended offer for Warner Chilcott by Actavis * Will acquire Warner Chilcott Plc in a stock-for-stock transaction valued at

20 May 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: Stock Traders Daily
$495.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks